Message Font: Serif | Sans-Serif
No. of Recommendations: 3
Hey Fools,

Oral Endothelin Receptor Antagonist Tracleer Meets Primary Endpoint In Pulmonary Arterial Hypertension Study

-- Actelion and Genentech announce positive results of Tracleer Phase III trial; Data will supplement US and European market authorization filing --

ALLSCHWIL, SWITZERLAND and SOUTH SAN FRANCISCO, CALIF., -- May 1, 2001 -- Actelion Ltd. (SWX New Market: ATLN) and Genentech, Inc. (NYSE: DNA) announced positive results today from a Phase III trial (BREATHE-1) of the first orally active endothelin receptor antagonist, Tracleerâ„¢ (bosentan) in pulmonary arterial hypertension (PAH). PAH is a potentially life-threatening chronic condition that that can severely compromise the function of the lungs and heart. In the BREATHE-1 trial, Tracleer demonstrated statistically significant improvements over placebo in the primary efficacy endpoint of the study, exercise capacity.

Rest of the article here:


Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.